COPD

Most hospitalized COPD flare-ups aren't severe by bedside criteria, experts say, and a tiered testing bundle could guide emergency care.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.

Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

Gerald Criner, MD, outlines which patients with advanced COPD may need oxygen, home NIV, or high-flow therapy and when to discuss goals of care.

The GOLD International COPD Conference will cover underdiagnosis, exacerbations, mucus, biologics, and a preview of the 2027 GOLD Report.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.